MULTIPLE MYELOMA

This study is testing a new type of personalized cell therapy called GC012F for people with multiple myeloma that has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to better hunt cancer,…

This study is testing if adding the drug siltuximab to a personalized dose of chemotherapy (melphalan) works better than the standard chemotherapy dose for people over 60 with multiple myeloma who are getting a stem cell transplant. The goal is to see if this combination helps co…

This study is testing a specific type of stem cell transplant using donated umbilical cord blood to treat patients with serious blood cancers and disorders. The procedure involves high-dose chemotherapy and radiation to wipe out the patient's diseased bone marrow before infusing …

This early-stage trial is testing a new CAR-T cell therapy called WS-CART-CS1 for people with multiple myeloma that has returned or stopped responding to at least three previous treatments. The study aims to find the safest dose and see if this therapy, which targets a protein ca…

This study is testing a new combination of four drugs for multiple myeloma, a cancer of the blood. The first part aims to find the safest dose for people whose cancer has come back. The second part will test how well the combination works for newly diagnosed patients with high-ri…

This study is testing whether a new type of cancer treatment called universal CAR-T cells is safe and effective for adults with multiple myeloma that has returned or stopped responding to other treatments. The treatment uses specially engineered immune cells from donors (not the …

This study is for people with hard-to-treat multiple myeloma who had a less-than-ideal response to a CAR-T cell therapy called ide-cel. Researchers want to see if adding a drug called nivolumab can improve their response. The trial will enroll 50 adults who received ide-cel but d…

This early-stage study is testing whether two drugs—elranatamab (given as an injection) and iberdomide (taken as a pill)—can be safely combined to treat multiple myeloma that has returned or stopped responding to previous treatments. The trial will enroll 87 adults who have alrea…

This study is testing whether a combination of four drugs is safe and effective for people with multiple myeloma that has returned or stopped responding to standard treatments, including CAR-T cell therapy. About 83 adults whose cancer worsened after at least two prior treatment …

This is an early-phase study testing the safety and initial effectiveness of a new type of CAR-T cell therapy for adults with relapsed or hard-to-treat blood cancers, including certain leukemias and lymphomas. Participants will receive a single infusion of these specially enginee…

This early-stage study is testing a new cell therapy called LVIVO-TaVec200 for patients with multiple myeloma that has come back or stopped responding to standard treatments. The study aims to find a safe and effective dose and see how the body handles the treatment. It is for ad…

This study is testing a combination of four medications to control multiple myeloma that has returned or stopped responding to prior treatments. It will involve about 43 adults whose cancer progressed after standard therapies. The main goal is to see how well this specific drug c…

This study is testing whether adding an experimental drug called etentamig to standard treatment works better for newly diagnosed multiple myeloma patients who aren't eligible for stem cell transplant. About 660 adults worldwide will receive either the new combination or current …

This study is testing whether following a specific diet can improve how well standard chemotherapy works and boost quality of life for people newly diagnosed with multiple myeloma, a type of blood cancer. Researchers will randomly assign 220 participants to either follow a prescr…

This study is testing a gentler, slower approach to starting treatment for very frail patients with multiple myeloma, a type of blood cancer. Researchers want to see if starting with two drugs and slowly adding a third helps patients stick with treatment longer and feel better. T…

This study is testing whether combining two existing multiple myeloma drugs—belantamab mafodotin and elotuzumab—is safe and more effective than using them separately. It's for patients whose cancer has returned or stopped responding after at least three prior treatments. Research…

This study aims to develop a safe process for giving the drug teclistamab to patients with advanced multiple myeloma in an outpatient or home setting, rather than requiring a hospital stay. It will enroll 15 patients who have tried at least three other treatments, along with thei…

This study is testing a new drug called belantamab for people with multiple myeloma, a type of blood cancer. It aims to find safe and effective doses, both when given alone and when combined with other standard treatments. The trial is for adults whose cancer has come back or sto…

This study is testing whether adding daratumumab to a standard three-drug combination (CyBorD) is safe and effective for treating kidney damage caused by monoclonal gammopathy of renal significance (MGRS). The trial will enroll 20 adults with MGRS-related kidney disease who have …

This large Phase 3 study is testing whether adding a new drug called teclistamab to standard maintenance therapy (lenalidomide) works better than lenalidomide alone for people with newly diagnosed multiple myeloma who have had a stem cell transplant. The goal is to help keep the …

This study is testing an experimental drug called linvoseltamab in combination with other cancer treatments for people with multiple myeloma that has returned or stopped responding to prior therapies. The main goals are to see if these combinations are safe and to find the best d…

This study is testing 12 different combinations of an experimental drug called selinexor with other approved myeloma medications. It aims to find safe and effective treatment options for adults whose multiple myeloma has returned after prior therapy or who are newly diagnosed. Th…

This study is testing whether a powerful cancer treatment called CAR-T therapy can be safely given to people with moderate to severe kidney problems. Researchers are adjusting the dose of the chemotherapy drugs given right before the CAR-T cells to see if it reduces serious side …

This study aims to see if a new personalized cell therapy, called anitocabtagene autoleucel, works better than current standard treatments for people with multiple myeloma that has come back or stopped responding to prior therapies. It will involve about 450 participants whose ca…

This study is testing a new type of CAR-T cell therapy for people with multiple myeloma who also have kidney problems. The therapy uses the patient's own modified immune cells to target the cancer. Researchers want to see if this treatment can help control the myeloma and improve…

This early-stage trial is testing the safety of a new type of cell therapy called P-BCMA-ALLO1 in adults with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses genetically modified immune cells from a donor, not the patient, aiming…

This study is testing several new drug combinations to find safe and effective treatments for multiple myeloma, a cancer of plasma cells in the bone marrow. It will enroll about 200 adults with the disease, including those whose cancer has come back after previous treatments and …

This study is testing whether a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) can help control multiple myeloma in patients whose cancer has returned or stopped responding to many treatments, including a recent CAR-T cell therapy. The goal is to see if th…

This study tests a personalized approach for treating newly diagnosed multiple myeloma, a blood cancer. It uses ultra-sensitive testing to detect tiny amounts of remaining cancer cells after initial treatment. Based on these results, patients receive different follow-up treatment…

This study is testing an experimental drug called JNJ-79635322 for people with multiple myeloma, a blood cancer, that has come back or stopped responding to at least three prior standard treatments. The main goal is to see how well the drug works to control the cancer and measure…

This early study is testing if a drug called Darzalex Faspro can safely lower harmful antibodies in patients with blood cancers. Lowering these antibodies may allow patients who are currently ineligible to receive a potentially life-saving stem cell transplant from a donor. The s…

This study is observing how well umbilical cord blood stem cells from unrelated donors work for patients with serious blood cancers and disorders. Researchers will track how quickly patients' blood counts recover, how often the transplant fails, and the rates of disease relapse a…

This study is testing a new cell therapy for patients whose blood cancers have returned or not responded to standard treatments. Researchers are giving patients specially engineered immune cells, called NK cells, which come from donated cord blood. The goal is to see if these mod…

This study is testing whether a new preparation method is safe for multiple myeloma patients with poor kidney function before they receive a CAR-T cell therapy called Carvykti. Standard preparation methods are not approved for these patients, creating an urgent need. The research…

This early-stage trial is testing a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. Doctors will collect patients' own immune cells, use CRISPR gene-editing technology to reprogram them to attack cancer, then infuse them back into…

This study is testing a two-drug maintenance therapy for people with multiple myeloma who have had a stem cell transplant. It is specifically for patients who still have very small amounts of cancer detectable in their bone marrow after the transplant. The goal is to see if the d…

This study is testing if taking a pill called selinexor after receiving CAR-T cell therapy can help keep multiple myeloma under control for longer. It is for patients whose cancer has come back after many treatments and who have high-risk features. The main goal is to see if addi…

This early-stage study is testing a new drug called belumosudil for people with multiple myeloma, a blood cancer, that has come back or stopped responding to standard treatments. The first part aims to find a safe dose. The second part will see if that dose, given alone or with a…

This small pilot study is testing if adding a specific prebiotic fiber to food can improve gut health for people with multiple myeloma or lymphoma undergoing a stem cell transplant. Researchers believe a healthier gut might lead to better recovery and survival. About 30 participa…

This study is testing whether using a simple early warning system can help patients with serious blood cancers like leukemia and lymphoma. The system uses regular checks of vital signs (like heart rate and breathing) to identify patients at high risk of dangerous complications. I…

This study is testing a new type of treatment called arlocabtagene autoleucel (BMS-986393), a CAR T-cell therapy, for adults with multiple myeloma that has returned or stopped responding to other treatments. The goal is to see how well this therapy works and how safe it is for pa…

This study aims to find better treatments for people with multiple myeloma, a blood cancer, that has come back or stopped responding to previous therapies. It will compare two new experimental drug combinations against current standard treatments. The trial will enroll about 795 …

This study is testing whether giving standard cancer treatments at home is as safe and effective as giving them in a clinic. It aims to see if receiving care at home reduces stress, improves quality of life, and is preferred by patients with advanced cancers. About 220 participan…

This early-stage study is testing a new drug called etentamig (ABBV-383) for adults with multiple myeloma that has returned or stopped responding to other treatments. The main goal is to find the safest and most effective dose and to closely monitor for side effects, including a …

This study is testing whether patients with advanced multiple myeloma can safely and effectively give themselves a cancer treatment called elranatamab at home. It involves 20 patients who have already tried several other treatments. The main goals are to check safety, see if home…

This study is testing if stopping a key injection drug (daratumumab or isatuximab) after about 18 months works as well as continuing it indefinitely for older adults with multiple myeloma who are not eligible for a stem cell transplant. About 570 participants who have already res…

This study aims to find the best treatment to help patients with multiple myeloma recover from severe kidney damage caused by the disease. It will compare three approaches: a blood-filtering procedure called plasma exchange, newer drug regimens based on daratumumab, and older dru…

This study aims to see if adding newer drugs (teclistamab or talquetamab) to a standard treatment works better for controlling newly diagnosed multiple myeloma. It will involve about 1,590 adults who are not planning to have a stem cell transplant. The main goal is to see if thes…

This Phase 3 trial compares two different three-drug combinations for adults newly diagnosed with multiple myeloma who cannot receive a stem cell transplant. Researchers want to see if the combination containing belantamab mafodotin (BRd) keeps the cancer from getting worse longe…

This early-stage study is testing whether a personalized cancer vaccine, made from a patient's own tumor and immune cells, is safe and works well when given alongside an approved drug called elranatamab. The goal is to see if this combination can better control multiple myeloma i…

This study is testing whether adding a new drug called motixafortide to a standard treatment (G-CSF) helps collect more stem cells from patients with multiple myeloma. These stem cells are needed for a transplant procedure that can help control the cancer. The trial will compare …

This early-stage study is testing a new treatment for multiple myeloma and related conditions. Doctors take a patient's own immune cells, train them in a lab to recognize and attack cancer cells, and then infuse them back into the patient. The main goals are to find the safest do…

This early study is testing a four-drug combination treatment for people newly diagnosed with multiple myeloma who also have kidney failure. Researchers want to see if this treatment can help control the cancer while also improving kidney function. The study will also look at whe…

This early-stage study is testing a new drug called JNJ-79635322 when combined with existing multiple myeloma treatments. Researchers aim to find safe and effective doses for 140 participants with different treatment histories. The trial will closely monitor side effects and how …

This early-stage study is testing whether combining two drugs, teclistamab and mezigdomide, is safe and effective for people with multiple myeloma that has come back or stopped responding to other treatments. The main goal is to find the safest dose and see if the combination can…

This study is testing the safety and effectiveness of three different experimental drug combinations for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The trial will enroll 160 participants to compare different treatment sequences, incl…

This trial is testing if a combination of two drugs, already approved for a type of skin cancer, can help control other rare cancers that share the same genetic change (a BRAF V600 mutation). It aims to enroll 30 adult patients with various rare or uncommon cancers to see if the …

This study is testing a new medicine called elranatamab, given as a weekly injection, against several standard combination therapies for multiple myeloma that has come back or stopped responding to previous treatments. It will involve about 492 adults whose cancer has progressed …

This study is testing whether the drug talquetamab can help control multiple myeloma in patients who have already received a specific CAR-T cell therapy (ide-cel) but whose cancer has returned or resisted treatment. The goal is to see if giving talquetamab after the CAR-T therapy…

This study is testing a personalized approach to keep multiple myeloma under control after a stem cell transplant. It uses a sensitive blood test to detect tiny amounts of leftover cancer cells and guide treatment with a drug called elranatamab. The goal is to see if this tailore…

This study is testing a new drug called JNJ-79635322 to see if it works better than an existing treatment for multiple myeloma, a type of blood cancer. It is for people whose cancer has come back or stopped responding after trying at least three other types of therapy. The main g…

This study is testing whether the drug elranatamab can help prevent multiple myeloma from returning or worsening in patients who have already received a specialized CAR-T cell therapy called idecabtagene vicleucel. The research involves about 32 adults with relapsed or hard-to-tr…

This study aims to find the best maintenance therapy to help keep high-risk multiple myeloma from returning after initial treatment. It will compare two oral drug combinations in 100 patients who have already completed standard therapy. The goal is to see which approach keeps pat…

This study tests whether the drug elranatamab can control multiple myeloma that has returned or stopped responding to previous treatments. It's for patients who have tried 1-3 different treatment combinations already. The approach is unique because patients who show a very deep r…

This early-stage study is testing a new combination of three drugs for patients with multiple myeloma that has come back or stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to see how well the combination works. The tria…

This study is testing if a new combination treatment is safe and effective for people with a hard-to-treat form of multiple myeloma that has spread to soft tissues. It combines a targeted cancer drug (talquetamab) with a short course of focused radiation aimed at one of the cance…

This study is testing a new combination of three drugs—elranatamab, lenalidomide, and dexamethasone—for people newly diagnosed with multiple myeloma, a blood cancer. The main goal is to see if this treatment can achieve a deep remission, meaning no detectable cancer cells remain …

This study is testing whether adding radiation therapy can improve outcomes for patients with multiple myeloma whose cancer has returned after receiving CAR-T cell therapy. The research will enroll 30 adults who still show active disease on scans at least 30 days after their CAR-…

This study aims to see how well and how safe a three-drug combination (SVd) works for adults with multiple myeloma in real-world clinics, outside of formal trials. It will follow at least 159 patients who have already tried 1-3 other treatments for their cancer. The main goal is …

This study is testing a new drug, surzetoclax, to see if it is safe and can help control multiple myeloma that has come back or stopped responding to other treatments. It will enroll about 130 adults who have already tried several other therapies. The drug will be tested both by …

This study is testing if the antiviral drug remdesivir can safely treat RSV (a common respiratory virus) in adults with weakened immune systems. Participants are people with cancer or autoimmune diseases who recently received treatments like stem cell transplants or specialized a…

This early-stage study is testing a new drug called linvoseltamab in people with advanced multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose, check for side effects, and see if the drug can effectively fight the c…

This study is testing a modified, two-step stem cell transplant procedure designed to be safer. It aims to reduce deaths caused by the transplant treatment itself in patients with various blood cancers and disorders. The trial compares two gentler preparation methods using lower …

This study is testing a new drug called etentamig (ABBV-383) for adults with multiple myeloma, a blood cancer, that has returned or is not responding to current treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for side effects. Ab…

This study is testing if a shorter course of radiation therapy is safe for people with multiple myeloma. Instead of the usual 2-3 weeks of daily treatments, researchers want to see if giving higher doses over just 1 to 10 days works as well and is safe. The trial will enroll 30 a…

This study is testing whether alternating between two different drug combinations is safe and effective for people newly diagnosed with standard-risk multiple myeloma. The trial will enroll 65 patients who are eligible for stem cell transplant. Researchers want to see if switchin…

This study is testing whether new drug combinations can better control multiple myeloma that has returned or stopped responding to previous treatments. It will compare two experimental approaches using the drugs elranatamab and daratumumab against a current standard therapy. The …

This study is checking the safety of a drug called teclistamab for Indian patients with advanced multiple myeloma, a type of blood cancer that has returned or stopped responding to previous treatments. It will include about 75 adults whose cancer has worsened despite trying at le…

This study is testing whether adding the chemotherapy drug cyclophosphamide to the immunotherapy drug elranatamab works better for people with multiple myeloma that has returned or stopped responding to other treatments. It is for adults whose cancer has specific features that mi…

This study is testing a new drug called etentamig, both alone and combined with other cancer medications, for people with multiple myeloma. It aims to find safe doses and see if these treatments can help control the cancer. About 440 adults with newly diagnosed or returning multi…

This study is testing whether adding a new drug called isatuximab to a standard three-drug combination is safe and more effective for people newly diagnosed with multiple myeloma who also have kidney problems. The goal is to see if this four-drug treatment helps more patients ach…

This study is testing a personalized cell therapy called ide-cel for people with multiple myeloma that has come back after many treatments and a stem cell transplant. Researchers want to see if the quality of a patient's own immune cells, used to make the therapy, affects how wel…

This study is testing a modified version of a CAR-T cell therapy called cilta-cel for people newly diagnosed with multiple myeloma who cannot receive a stem cell transplant. It aims to see if changing how the therapy is prepared and given can make it work better and be safer. The…

This study is testing if a drug called elranatamab can help control high-risk multiple myeloma when given both before and after a patient's own stem cell transplant. The goal is to see if this approach can eliminate any remaining cancer cells and keep the disease from returning. …

This study is testing a new three-drug combination (carfilzomib, iberdomide, and dexamethasone, called KID) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The trial aims to find the safest dose and see how well this combination works…

This study is testing a new oral drug called enzomenib for people with advanced blood cancers like acute leukemia that have come back or not responded to other treatments. The main goals are to find a safe and effective dose and to see if the drug, given alone or with standard ch…

This study aims to see if a new drug called iberdomide is better than the current standard drug, lenalidomide, at keeping multiple myeloma from coming back after a patient's own stem cell transplant. It will involve over 1,200 people recently diagnosed with this blood cancer. The…

This study aims to see if matching existing cancer drugs to the specific genetic changes found in a person's tumor can help control advanced cancers. It is for adults with certain advanced solid tumors, lymphoma, or multiple myeloma who have run out of standard treatment options.…

This study is testing whether a monthly monitoring program can help older adults with multiple myeloma maintain their independence. The program checks six key areas of health like mobility and memory to catch problems early. Researchers want to see if patients can stick with the …

This early-stage trial is testing a new oral medication called KTX-1001 for adults with advanced multiple myeloma that has returned or stopped responding to standard treatments. The study aims to find the safest and most effective dose and see if the drug helps control the cancer…

This study is testing a new combination of two drugs, etentamig and iberdomide, for adults whose multiple myeloma has come back or stopped responding to other treatments. The main goals are to find a safe and tolerable dose and to see if the combination can help control the disea…

This program provides the investigational drug selinexor to patients with certain cancers who have run out of standard treatment options and don't qualify for ongoing clinical trials. It allows doctors to request the drug for eligible patients before it receives full regulatory a…

This early-stage trial is testing the safety and best dose of a drug called venetoclax when combined with other standard multiple myeloma medications. It is for patients with a specific genetic feature in their cancer cells called t(11;14). The goal is to see if adding venetoclax…

This study is testing whether multiple myeloma patients who show no detectable cancer after stem cell transplant can safely stop their long-term maintenance medications. Researchers will follow 50 patients who have been on maintenance therapy for at least two years and have undet…

This study is testing a new drug called AZD0305 for people with multiple myeloma, a type of blood cancer, that has come back or stopped responding to at least three prior treatments. The main goals are to find a safe dose and see if the drug can help control the cancer, either by…

This study provides continued access to the drug elranatamab for people with multiple myeloma who benefited from it in earlier Pfizer-sponsored trials. It allows up to 80 participants to keep receiving the treatment while researchers monitor its long-term safety. The goal is to c…

This early-stage trial is testing a new type of CAR T-cell therapy called TriPRIL for adults with multiple myeloma that has returned or stopped responding to standard treatments. Researchers will give patients a single infusion of their own modified immune cells to try to fight t…

This study is for people with multiple myeloma who have already had a stem cell transplant. It compares two maintenance treatments to see which one is better at keeping the cancer from coming back. One group gets a pill called iberdomide, and the other gets that same pill plus an…

This study is testing if two already-approved drugs for multiple myeloma, teclistamab and talquetamab, can be safely given to patients at home instead of in the hospital. Researchers will give patients preventive medications before treatment to try to reduce common and serious si…

This study is testing whether adding a drug called isatuximab to the standard maintenance drug lenalidomide can better control high-risk multiple myeloma after a patient's own stem cell transplant. It will involve about 61 adults who have this aggressive form of the blood cancer …

This study is comparing a new investigational drug called etentamig against standard available therapies for adults with multiple myeloma that has come back (relapsed) or stopped responding to treatment (refractory). Around 380 participants worldwide will be randomly assigned to …

This early-stage study is testing a one-time treatment called BMS-986453, a type of CAR-T cell therapy, for people newly diagnosed with multiple myeloma who are not planning to have a stem cell transplant. The main goal is to see if this single treatment is safe and can help cont…

This early-phase study is testing the safety of a new drug combination used to collect a patient's own stem cells for a transplant. The goal is to find the highest safe dose of the drug carfilzomib when used with other standard medications for this collection process. The study w…

This study is testing whether adding a new drug called linvoseltamab to standard maintenance therapy can help eliminate any remaining multiple myeloma cells in patients' bodies. The research aims to help patients achieve and maintain 'minimal residual disease negative' status, me…

This study is testing the safety and effectiveness of two different drug combinations for older adults newly diagnosed with multiple myeloma, a blood cancer. It is for patients aged 65 and older who are not eligible for a stem cell transplant. The goal is to see if these combinat…

This study is testing whether some multiple myeloma patients who are in a very deep, sustained remission can safely stop their long-term maintenance therapy. It will enroll about 70 patients who have been on therapy for at least two years and have no signs of cancer in very sensi…

This study is testing a new combination of two drugs, mezigdomide and elranatamab, for people with multiple myeloma that has come back or stopped responding to previous treatments. The main goals are to find the safest and most effective dose and to see how well the combination w…

This study is testing a personalized immune cell therapy called BCMA-CAR-T for young adults newly diagnosed with multiple myeloma, a blood cancer. Researchers want to see if combining this therapy with a stem cell transplant is safe and works better than the cell therapy alone. T…

This early-stage study is testing an investigational drug called cevostamab in a small group of Chinese patients whose multiple myeloma has returned or stopped responding to other treatments. The main goals are to understand how the drug behaves in the body, check its safety, and…

This early-stage study is testing whether collecting a patient's own blood-forming stem cells and giving them back alongside CAR-T therapy is safe and feasible for people with aggressive blood cancers that have come back or not responded to other treatments. The main goals are to…

This study is testing a lower-dose version of a three-drug combination (isatuximab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who are older or frail. The goal is to see if using lower doses can effectively control the cancer while causing f…

This study is testing a new approach to collecting a patient's own stem cells for a transplant to treat blood cancers like multiple myeloma and lymphoma. The goal is to see if using a standard drug (G-CSF) first and only adding a second drug (Plerixafor) if needed can successfull…

This early-stage study is testing a new drug called CCS1477 (inobrodib) in patients with advanced blood cancers that have returned or stopped responding to standard treatments. The main goals are to check if the drug is safe, what side effects it causes, and if it shows signs of …

This program provides access to a cell therapy called ide-cel for people with multiple myeloma when the specific batch made for them doesn't pass all the standard quality checks for commercial sale. It's for patients who are clinically stable and for whom making a new batch isn't…

This is a very early study to check the safety and first signs of effectiveness of a new treatment called JY232 injection for people with multiple myeloma that has come back or stopped responding to other therapies. JY232 is a type of CAR-T cell therapy, where a patient's own imm…

This study is testing a two-part treatment for patients with very high-risk multiple myeloma, a blood cancer, that hasn't responded well to standard first-line therapy. Doctors will collect a patient's own stem cells and immune cells, give a stem cell transplant, and then infuse …

This study is testing whether patients with newly diagnosed multiple myeloma or amyloidosis can safely delay or avoid stem cell transplant. Researchers will use a sensitive blood test to measure how well patients respond to initial drug therapy. If patients show a very deep respo…

This study is testing a personalized cell therapy for people with metastatic cancer that has not responded to standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to better recognize and attack their specific cancer, and then infus…

This study is testing whether a personalized support plan helps older adults recover their physical strength and daily function faster after receiving CAR-T cell therapy for blood cancers like lymphoma or multiple myeloma. The plan is based on a detailed health assessment and inc…

This study is testing a combination of four drugs to control multiple myeloma in older adults who are not eligible for a stem cell transplant. The treatment plan is flexible—a fourth drug is added only if a patient's initial response isn't deep enough. The goal is to see how well…

This early-stage study is testing a new type of personalized immune cell therapy (called arlocabtagene autoleucel) when given alongside other investigational drugs. It aims to find safe doses and see if these combinations can help control multiple myeloma that has returned or sto…

This study is testing a personalized treatment approach for adults aged 65+ with newly diagnosed multiple myeloma, a blood cancer. The goal is to adjust medication strength based on each person's changing health and frailty level over time, aiming to better balance effectiveness …

This large, late-stage study is testing whether adding an experimental drug called linvoseltamab to a standard treatment regimen works better for controlling multiple myeloma. It will involve 1,000 adults newly diagnosed with this blood cancer who are not candidates for a stem ce…

This early-stage study is testing the safety of two new drug combinations for people with multiple myeloma that has returned or stopped responding to standard treatments. About 90 participants will receive either a three-drug combination or a two-drug combination to see how well …

This is an early-stage study to test the safety and find the right dose of a new type of CAR-T cell therapy for people with multiple myeloma that has come back or stopped responding to other treatments. The therapy, called CAR19-BCMA, is designed to attack cancer cells in two way…

This study is testing a combination of four medications for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see how well this new combination controls the cancer and for how long. About 50 participants will receive the trea…

This program provides early access to the drug venetoclax for patients with certain blood cancers like leukemia and lymphoma before it is fully approved in their country. It is for patients who have no other suitable treatment options and do not qualify for ongoing clinical trial…

This early-stage trial is testing the safety of a new type of personalized cell therapy for people with advanced multiple myeloma that has stopped responding to standard treatments. Doctors will collect and genetically modify a patient's own immune cells (T cells) to help them fi…

This early-stage study is testing the safety and initial effects of a new cell therapy called AZD0120 in adults with multiple myeloma. The therapy involves modifying a patient's own immune cells to attack two targets on the cancer cells (BCMA and CD19). The main goal is to see ho…

This study is testing new combinations of experimental drugs for people with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find safe doses and see if these combinations can help control the cancer. The study will enroll about…

This large Phase 3 study is comparing two different drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or are delaying a stem cell transplant. Researchers want to see if adding a new drug called elranatamab to a standard treatment is more …

This study observes how patients with multiple myeloma and weakened immune systems use HyQvia treatment during routine medical care. Researchers will track how the treatment is given, including dosage, timing, and any side effects, to understand real-world practice. The study inv…

This study is testing if taking a daily pill called iberdomide can help patients with multiple myeloma live longer without their cancer getting worse after they receive a powerful one-time treatment called CAR-T cell therapy. Currently, doctors just monitor patients after CAR-T t…

This program provides access to an experimental cell therapy called cilta-cel for patients with serious multiple myeloma who have run out of standard treatment options. The therapy uses modified immune cells to target cancer cells, but these particular doses don't meet all the us…

This study is testing an experimental drug called linvoseltamab for people newly diagnosed with multiple myeloma, a type of blood cancer. The trial aims to find the right dose, check for side effects, and see how well the drug shrinks tumors in 149 participants. It includes both …

This is a first-in-human study to test the safety and how the body processes a new drug called TQB2934 for multiple myeloma, a type of blood cancer. The drug is given as a shot under the skin and works by guiding the body's own immune T-cells to find and kill the cancer cells. Th…

This study is testing a new combination of two oral drugs, mirdametinib and sirolimus, for adults with advanced multiple myeloma that has returned or stopped responding to other treatments. The trial aims to find a safe dose and see if the drugs can help control the cancer in pat…

This study allows multiple myeloma patients who benefited from daratumumab treatment in previous Janssen trials to continue receiving it. The main goal is to provide ongoing treatment access while monitoring long-term safety. About 500 participants who are already responding well…

This study is testing whether a new drug called cemsidomide, when given with a standard steroid (dexamethasone), can help control multiple myeloma that has come back or stopped responding to other treatments. It is for adults who have already tried at least three different types …

This study is testing a new diagnostic platform called IT-TCP that analyzes tumor samples from patients with high-risk cancers. Researchers will collect samples from 300 patients with various cancers including leukemia, pancreatic cancer, and melanoma to see if this detailed anal…

This study is testing a new type of PET scan for people with or suspected of having multiple myeloma, a blood cancer. The new scan uses a special probe (68Ga-NB381) designed to attach to a protein (CD38) found on the cancer cells, potentially making the cancer easier to see. Rese…

This study is testing if a new type of imaging scan can better detect multiple myeloma, a blood cancer, compared to the scan currently used. Researchers want to see if this new scan can find returning disease earlier, which could help doctors start treatment sooner. About 60 adul…

This early-stage study is testing a new radioactive tracer called [89Zr]DFO-YS5 for PET scans in patients with multiple myeloma. The tracer is designed to attach to a specific protein (CD46) found on myeloma cancer cells, potentially helping doctors see the cancer more clearly. R…

This study is testing a new blood test designed to detect many types of cancer early, before symptoms appear. It will involve 7,000 people, both with and without cancer, to see if the test can accurately spot cancer signals and identify where in the body the cancer started. The t…

This study is testing a new type of PET scan to see if it can better detect and track multiple myeloma, a type of blood cancer. It will compare the new scan, which uses a tracer called [68Ga]Ga-PentixaFor, to a standard FDG-PET scan in 45 patients who are either newly diagnosed o…

This study is testing a personalized exercise program designed to prevent falls in people being treated for multiple myeloma, a type of blood cancer. Researchers want to understand what makes these patients more likely to fall and see if regular strength and balance training can …

This study is testing whether a medication called IgPro20 can help prevent infections in people with multiple myeloma who have low antibody levels. The research focuses on patients receiving bispecific antibody therapy, which can increase infection risk. Participants will be rand…

This study is testing whether giving regular antibody infusions (Gammagard) from the start of a new cancer treatment can prevent serious infections better than waiting to treat infections only after they occur. It involves 183 adults with multiple myeloma who are receiving a spec…

This study is testing whether two different drug combinations can delay or prevent the development of multiple myeloma in people who have high-risk early-stage disease. Researchers will enroll 50 adults with smoldering myeloma to receive either teclistamab plus daratumumab or tal…

This study is testing whether cancer patients prefer to receive their standard drug treatments at home instead of in a clinic. Researchers want to see if home-based care reduces the burden of travel and improves treatment satisfaction and quality of life for patients. A specializ…

This study is testing whether a home-based program can help reduce fatigue and improve quality of life for older adults living with multiple myeloma. Participants will follow a gentle daily activity plan that includes mindfulness, flexibility, and walking, while also receiving we…

This study is testing if an 8-week, home-based exercise program done before a stem cell transplant can help multiple myeloma patients. Researchers want to see if this 'prehabilitation' improves patients' muscle strength, physical fitness, and quality of life compared to patients …

This study is comparing two different combinations of anti-nausea medications to see which one works better at preventing severe, delayed nausea and vomiting in multiple myeloma patients undergoing high-dose chemotherapy and a stem cell transplant. It involves 92 patients across …

This study is testing if adding early palliative (comfort) care to standard cancer treatment improves well-being for patients with multiple myeloma or aggressive lymphoma. It will involve 144 patients, and some of their caregivers, who will be randomly assigned to receive either …

This study aims to find the best premedication to reduce allergic reactions to a drug called motixafortide, which helps collect stem cells for a transplant in multiple myeloma patients. It will compare the standard steroid, dexamethasone, against another steroid, methylprednisolo…

This study is testing whether a 10-week exercise program is practical and helpful for people with multiple myeloma who are getting chemotherapy before a stem cell transplant. Researchers want to see if patients can and want to participate in a tailored exercise plan, delivered in…

This small pilot study is testing whether an 8-week home exercise program delivered via telehealth is practical and acceptable for older adults with multiple myeloma who are preparing for a stem cell transplant. The goal is to see if this 'prehabilitation' helps patients maintain…

This study is testing a specially designed exercise program for people with multiple myeloma who are preparing for a stem cell transplant. The goal is to see if this physical activity program can reduce the severe fatigue often experienced during cancer treatment and improve pati…

This study aims to see if adding a non-addictive pain medication (toradol) to standard opioid painkillers can better manage pain and reduce overall opioid use after a specific leg surgery. It involves 60 adult patients with bone cancer who are having a rod placed in their thigh b…

This study aims to understand if using cannabis (marijuana) affects the quality of life and symptoms of people with multiple myeloma who are receiving chemotherapy. Researchers will follow 700 newly diagnosed patients, comparing those who use cannabis to those who do not, by havi…

This study is testing a new tool that uses an AI chatbot to create a personalized list of questions for patients with lymphoma or multiple myeloma to ask during their doctor's appointments. Researchers want to see if this helps patients feel more confident talking to their doctor…

This study aims to better understand multiple myeloma by analyzing the genetic makeup of tumors from 100 patients over two years. Researchers will use advanced sequencing techniques on blood and tumor samples collected during standard care procedures to identify genetic patterns …

This study aims to find early signs of multiple myeloma, a type of blood cancer, in people before they develop symptoms. Researchers will screen over 1,600 adults in the Charlotte area who are at higher risk, primarily focusing on Black/African American individuals and relatives …

This study aims to understand the inherited genetic factors that cause lymphoma, leukemia, and related cancers within families. Researchers are recruiting individuals and their family members who have a personal or family history of these diseases. The main goal is to collect DNA…

This study is creating a large registry of patients in Ohio with multiple myeloma and related blood disorders. Researchers will track patients' treatments, health outcomes, and quality of life over time to understand these diseases better. The registry also helps connect patients…

This study is creating a large registry to track the health of older adults (age 50+) with blood cancers like multiple myeloma. Researchers will collect information through questionnaires and simple physical tests to understand how frailty and aging affect these patients. The goa…

This study is creating a large collection of blood, urine, and tissue samples from up to 10,000 patients with amyloid diseases, like multiple myeloma. The purpose is to store these samples and related health information in a research 'biobank' for future scientists to study. This…

This study is testing whether a drug called Imuthiol (Zn-DDC) can kill cancer cells in the lab, specifically for blood cancers like multiple myeloma and leukemia. Researchers will collect bone marrow samples from 70 patients to see how cancer cells respond to Imuthiol alone and c…

This study collects blood, tissue, and other samples from adults with cancer or pre-cancerous conditions. The goal is to understand how cancer works and why treatments affect people differently. Researchers will bank these samples for future lab studies to help develop better imm…

This study is testing a new tool called PRIME that helps older adults with blood cancers and their doctors discuss treatment priorities. It compares whether using this tool helps patients feel their final treatment decision better matches their personal values compared to standar…

This study aims to collect blood, tissue, and fluid samples from adults with lymphoma, multiple myeloma, or related blood cancers. The goal is to help researchers better understand the biology of these diseases in the lab. This is a sample collection study only and does not provi…

This study aims to understand why some multiple myeloma patients respond better to CAR-T cell therapy than others. Researchers will observe 25 patients, measuring specific immune cells (monocytes) before and after treatment. The goal is to find markers that can predict treatment …

This study aims to understand why some people with early, symptom-free blood cell changes develop the cancer multiple myeloma, while others do not. It will follow 30,000 people who are at higher risk due to family history or race. The goal is to find markers that can predict who …

This study aims to understand why a specific gene (IGLV1-44) causes two rare and serious blood disorders: AL amyloidosis and POEMS syndrome. Researchers will analyze blood and bone marrow samples from 100 patients to identify unique patterns in the gene. The goal is to improve ea…

This study is not a treatment trial. Its purpose is to monitor the long-term health of people who have already received a specific CAR-T cell therapy (cilta-cel) for multiple myeloma. Researchers will follow about 295 participants for up to 15 years to check for any delayed side …

This study aims to monitor the long-term health of 500 patients who have already received CAR-T cell therapy for various blood cancers in earlier trials. Researchers will follow these patients for up to 15 years to check for any late-developing side effects, such as new cancers o…

This study aims to learn from real-world experience by observing how well FDA-approved targeted cancer drugs work for patients with advanced solid tumors, lymphoma, or multiple myeloma. It enrolls over 4,000 patients whose tumors have specific genetic changes that suggest a drug …

This study is building a large, long-term database of health information and biological samples from people with cancer, people at risk for cancer, and healthy volunteers. The goal is to collect this data to help researchers better understand what causes cancer and how to prevent…

This study aims to understand if exposure to hazardous chemicals during firefighting increases early signs that can lead to blood cancers. Researchers will enroll 300 Charlotte firefighters aged 40-49 with at least 5 years of experience to test their blood for these early markers…

This study collects tissue and fluid samples from adults and children with cancer. The goal is to gather these samples for research to help scientists better understand cancer and develop new tests and models for future treatments. Samples are collected during procedures patients…

This study aims to collect and store blood and tissue samples from 6,000 patients with multiple myeloma and related conditions. Researchers will gather samples and track treatment information over time to create a resource for future studies. The goal is to help scientists better…

This study aims to understand why multiple myeloma affects different racial and ethnic groups differently. Researchers will survey 4,000 patients in California who were diagnosed within the last five years to learn about their risk factors, treatment, and quality of life. The goa…

This study compares how well a common blood thinner (apixaban) prevents blood clots in two groups: patients newly diagnosed with multiple myeloma (a blood cancer) and patients undergoing total knee replacement surgery. Researchers want to understand if the medication works differ…

This study is testing a new imaging agent used with PET/CT scans to see if it can better detect and measure certain blood cancers and rare tumors. It involves about 30 adult patients with conditions like non-Hodgkin lymphoma, multiple myeloma, or specific rare diseases. The goal …

This study aims to understand if sleep apnea influences the progression of two related blood conditions: MGUS and multiple myeloma. Researchers are enrolling 200 patients who are already scheduled for a standard bone marrow biopsy. They will collect these samples to compare gene …

This study aims to understand how short-term dietary changes affect gut bacteria in people with early, pre-cancerous blood conditions (MGUS or SMM). Researchers will remotely enroll 200 participants across the US to follow a plant-based diet or take specific supplements for two w…

This study aims to collect real-world information on how cancer patients experience and report their symptoms from home during treatment. About 25 adults with breast, lung, ovarian, or blood cancers will use an online platform to complete weekly surveys for at least 12 weeks. The…

This study aims to understand why certain blood and lymph cancers sometimes run in families. Researchers are enrolling families where at least two blood relatives have been diagnosed with these cancers. The goal is to learn how genetics and environmental factors might work togeth…

This study is creating a large registry of 2000 adults with plasma cell disorders like multiple myeloma and amyloidosis. Participants complete health assessments about their daily function, medical conditions, and quality of life over time, and can optionally give blood samples f…

This study is creating a national registry to track how multiple myeloma is treated in Germany. It will follow 2,200 patients for up to five years to document their treatments, outcomes, and quality of life. The goal is to understand real-world treatment patterns and collect data…

This study is collecting information about how patients with blood cancers and disorders respond to stem cell transplants in the high-altitude Tibetan region. Researchers are enrolling 1000 patients and their donors to track treatment patterns, recovery times, survival rates, and…

This study aims to understand why many patients develop low blood cell counts after receiving CAR-T therapy for certain blood cancers. Researchers will collect genetic and tissue samples from patients before and after treatment to look for inherited or acquired gene changes linke…

This study aims to understand how a specific sugar modification on certain proteins might cause AL amyloidosis, a serious disease where proteins clump together and damage organs. Researchers will analyze blood and bone marrow samples from 100 people with related blood cell disord…

This study collects health information from patients receiving stem cell transplants for various blood cancers and immune disorders. Researchers will track 2,000 patients over time to gather data on survival rates and treatment complications. The goal is to build a comprehensive …

This study aims to gather detailed information on many different blood diseases in China, including cancers like leukemia and lymphoma, and conditions like hemophilia. It will follow 2,300 patients to learn how common these diseases are, what treatments patients receive, how well…

This study is collecting tissue and blood samples from cancer patients over time to create a research resource called a biobank. Researchers will analyze these samples to understand how cancer changes during treatment and why some treatments stop working. The goal is to help scie…

This study aims to understand if CAR-T cell therapy, a powerful new cancer treatment, might affect heart function in the first few days after patients receive it. Researchers will follow 60 patients with blood cancers, performing heart ultrasounds before and shortly after their C…

This study is a testing service, not a treatment. It aims to analyze tumor samples from patients who received a specific Bristol-Myers Squibb gene therapy for blood cancers and later developed a second, unrelated cancer. The goal is to check if genetic material from the original …

This study aims to understand if CAR-T therapy, a powerful cancer treatment, reduces the body's long-term protection from common vaccines like measles, mumps, and tetanus. Researchers will observe 45 adults with blood cancers, measuring their antibody levels before and after CAR-…